Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • FLT3 inhibitors potentially im...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
FLT3 inhibitors potentially improve response rates in acute myeloid leukemia harboring t(6;9)(<i>DEK::NUP214</i>): The Mayo Clinic experience

FLT3 inhibitors potentially improve response rates in acute myeloid leukemia harboring t(6;9)(<i>DEK::NUP214</i>): The Mayo Clinic experience

Not available.

Bibliographic Details
Main Authors: Clifford M. Csizmar, Antoine N. Saliba, Patricia T. Greipp, Hassan Alkhateeb, Kebede H. Begna, James M. Foran, Naseema Gangat, William J. Hogan, C. Christopher Hook, Mark R. Litzow, Abhishek A. Mangaonkar, Jeanne M. Palmer, Animesh Pardanani, Mithun V. Shah, Ayalew Tefferi, Mehrdad Hefazi Torghabeh, Alexandra P. Wolanskyj-Spinner, Mrinal M. Patnaik, Scott H Kaufmann, Aref Al-Kali
Format: Article
Language:English
Published: Ferrata Storti Foundation 2024-06-01
Series:Haematologica
Online Access:https://haematologica.org/article/view/11657
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://haematologica.org/article/view/11657

Similar Items

  • P394: INSIGHTS INTO PATIENT-DERIVED XENOGRAFT MODELS FOR DEK-NUP214 LEUKEMIA
    by: F. Charles Cano, et al.
    Published: (2022-06-01)
  • Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia
    by: Naseema Gangat, et al.
    Published: (2022-06-01)
  • Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor
    by: Naseema Gangat, et al.
    Published: (2023-01-01)
  • Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemia
    by: Naseema Gangat, et al.
    Published: (2023-08-01)
  • Adverse karyotype subcategories in acute myeloid leukemia display significant differences in mutation composition and transplant-augmented survival
    by: Ayalew Tefferi, et al.
    Published: (2022-09-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs